Jorge Loredo, DO
Internal Medicine · Miami, FLNPI 1073567640
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 824 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 824 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- AbbVie$1K
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- Boehringer Ingelheim$1K
- GSK$929
- plus $7K from 31 others
Across 21 payments — averaging $502.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$9K
- Akebia Therapeutics Inc$1K
- Cipla USA Inc.$866
What the payments were for
- Food & beverage$15,153100%
- Education$300%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 120 | $2,580 |
| AbbVie(2 entities) | 85 | $1,318 |
| Lilly USA, LLC | 80 | $1,310 |
| Novo Nordisk | 67 | $1,231 |
| Boehringer Ingelheim | 61 | $1,115 |
| GSK | 54 | $929 |
| Pfizer | 34 | $687 |
| Novartis | 33 | $594 |
| Kowa Pharmaceuticals America, Inc. | 32 | $585 |
| Sanofi-aventis U.S. LLC | 29 | $559 |
| Amgen(2 entities) | 32 | $538 |
| Johnson & Johnson | 24 | $450 |
| Merck | 23 | $438 |
| Amneal Pharmaceuticals LLC | 20 | $340 |
| Scilex Pharmaceuticals Inc. | 17 | $323 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $309 |
| Amarin Pharma, Inc. | 14 | $271 |
| Bayer | 9 | $193 |
| Corcept Therapeutics | 8 | $158 |
| Optinose US, Inc. | 8 | $140 |
| Phathom Pharmaceuticals, Inc. | 8 | $138 |
| Abbott | 6 | $130 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $125 |
| Ironwood Pharmaceuticals, Inc | 4 | $96 |
| Biohaven Pharmaceuticals, Inc. | 4 | $92 |
| Idorsia Pharmaceuticals US Inc | 6 | $91 |
| Exact Sciences | 4 | $89 |
| E.r. Squibb & Sons, L.L.C. | 3 | $67 |
| Currax Pharmaceuticals LLC | 4 | $55 |
| Astellas Pharma US Inc | 3 | $47 |
| Evoke Pharma, Inc. | 2 | $42 |
| Teva Pharmaceuticals USA, Inc. | 1 | $38 |
| Boston Scientific | 1 | $36 |
| IBSA Pharma Inc. | 1 | $20 |
| Medicure Pharma Inc. | 1 | $19 |
| Eisai Inc. | 1 | $17 |
| Adamas Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$15,183 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 128 | $133,306 |
| JardianceEmpagliflozin | 77 | $62,593 |
| MounjaroTirzepatide | 45 | $55,833 |
| XareltoRivaroxaban | 38 | $49,733 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $42,424 |
| TrulicityDulaglutide | 34 | $41,541 |
| LinzessLinaclotide | 48 | $29,645 |
| ProliaDenosumab | 15 | $26,464 |
| EntrestoSacubitril/Valsartan | 16 | $23,968 |
| EliquisApixaban | 22 | $23,012 |
| FarxigaDapagliflozin Propanediol | 16 | $22,756 |
| JanuviaSitagliptin Phosphate | 16 | $18,040 |
| LivaloPitavastatin Calcium | 28 | $16,161 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $13,464 |
| VascepaIcosapent Ethyl | 26 | $11,360 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,231 | $133,306128 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,310 | $97,37479 claims |
| Boehringer IngelheimJardiance | $1,115 | $62,59377 claims |
| Johnson & JohnsonXarelto | $450 | $49,73338 claims |
| GSKTrelegy Ellipta | $929 | $42,42454 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $2,580 | $36,21934 claims |
| AbbVieLinzess, Synthroid | $1,318 | $32,18980 claims |
| AmgenProlia | $538 | $26,46415 claims |
| NovartisEntresto | $594 | $23,96816 claims |
| PfizerEliquis | $687 | $23,01222 claims |
| MerckJanuvia | $438 | $18,04016 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $585 | $16,16128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Miami
- Haytham ElgammalMiami$2.2M
- Richard AguilarMiami$239K
- Maria Delgado LelievreMiami$80K
- Marlow HernandezMiami$58K
- Steven CohnMiami$47K
- Joseph PiperatoMiami$45K
- Simon AbelsonMiami$44K
- Joel Brooks TamayoMiami$42K
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.